Two other preclinical studies showed that combining the HMA decitabine with anti-CTLA-4 (15) or azacytidine with anti-PD-L1 (16) sensitized murine ovarian cancers to immune checkpoint blockade therapy by increasing interferon and chemokine signaling from the tumor cells to recruit and activate host immune cells. This evidence concerns the gene CTLA4 and ovarian cancer.